Effect of Previous or Simultaneous Immunization with Canarypox Expressing Cytomegalovirus (CMV) Glycoprotein B (gB) on Response to Subunit gB Vaccine plus MF59 in Healthy CMV-Seronegative Adults

Development of a vaccine for prevention of congenital cytomegalovirus (CMV) disease is a priority. This study evaluated a “prime-boost” strategy by comparing the safety and immunogenicity of 3 doses of subunit CMV glycoprotein B (gB) vaccine plus MF59 (a squalene-in-water emulsion), 2 doses of a can...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2002-03, Vol.185 (5), p.686-690
Main Authors: Bernstein, David I., Schleiss, Mark R., Berencsi, Klara, Gonczol, Eva, Dickey, Michelle, Khoury, Phil, Cadoz, Michel, Meric, Claude, Zahradnik, John, Duliege, Anne-Marie, Plotkin, Stanley
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Adolescent
Adult
Antibodies
Antibodies, Viral - blood
Bacteriology
Biological and medical sciences
Concise Communication
Cytomegalovirus
Cytomegalovirus infections
Cytomegalovirus Infections - prevention & control
Cytomegalovirus Vaccines - administration & dosage
Cytomegalovirus Vaccines - immunology
Dosage
Enzyme linked immunosorbent assay
Fundamental and applied biological sciences. Psychology
Glycoproteins
Humans
Immunization
Immunization Schedule
Immunization, Secondary
Lymphocyte Activation
Microbiology
Middle Aged
Pain
Placebos
Polysorbates - administration & dosage
Squalene - administration & dosage
Squalene - immunology
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, Subunit - administration & dosage
Vaccines, Subunit - immunology
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Envelope Proteins - metabolism
Viral Vaccines - administration & dosage
Viral Vaccines - genetics
Viral Vaccines - immunology
Virology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Development of a vaccine for prevention of congenital cytomegalovirus (CMV) disease is a priority. This study evaluated a “prime-boost” strategy by comparing the safety and immunogenicity of 3 doses of subunit CMV glycoprotein B (gB) vaccine plus MF59 (a squalene-in-water emulsion), 2 doses of a canarypox recombinant vaccine expressing CMVgB (ALVAC-CMVgB) followed by 2 doses of the subunit gB vaccine, 3 doses of both vaccines administered concomitantly, and placebo in 105 healthy, CMV-seronegative adults. Systemic adverse events were rare, but local reactions were common in all groups. After the first subunit vaccination, neutralizing antibody titers in the prime-boost group were comparable to those in subjects receiving 2 subunit vaccinations, indicating a priming effect of ALVAC-CMVgB. However, after the final dose, antibody and cell-mediated immune responses were not significantly different among the groups. All 3 vaccine regimens induced high-titer antibody and lymphoproliferative responses, but no benefit for priming or simultaneous vaccination was detected.
ISSN:0022-1899
1537-6613
DOI:10.1086/339003